Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) EBITDA Margin (2016 - 2025)

Celldex Therapeutics has reported EBITDA Margin over the past 16 years, most recently at 67319.01% for Q4 2025.

  • Quarterly results put EBITDA Margin at 67319.01% for Q4 2025, down 6314318.0% from a year ago — trailing twelve months through Dec 2025 was 16717.01% (down 1446834.0% YoY), and the annual figure for FY2025 was 16727.83%, down 1447916.0%.
  • EBITDA Margin for Q4 2025 was 67319.01% at Celldex Therapeutics, down from 7784.79% in the prior quarter.
  • Over the last five years, EBITDA Margin for CLDX hit a ceiling of 384.14% in Q2 2021 and a floor of 67319.01% in Q4 2025.
  • Median EBITDA Margin over the past 5 years was 6228.14% (2021), compared with a mean of 10337.64%.
  • Peak annual rise in EBITDA Margin hit 1400894bps in 2025, while the deepest fall reached -6314318bps in 2025.
  • Celldex Therapeutics' EBITDA Margin stood at 6228.14% in 2021, then skyrocketed by 75bps to 1557.04% in 2022, then soared by 34bps to 1019.92% in 2023, then tumbled by -309bps to 4175.83% in 2024, then crashed by -1512bps to 67319.01% in 2025.
  • The last three reported values for EBITDA Margin were 67319.01% (Q4 2025), 7784.79% (Q2 2025), and 7703.88% (Q1 2025) per Business Quant data.